Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.50 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 5/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29352397 | 1.00 | NPC1 (0.58) | NPC1RXFP1RAB9AATMMEN1 | |
| SCHEMBL12987394 | 0.88 | NPC1 (0.53) | NPC1RXFP1RAB9AATMMEN1 | |
| SCHEMBL8592351 | 0.79 | MEN1 (0.53) | NPC1RXFP1RAB9AATMMEN1 | |
| SCHEMBL18573277 | 0.79 | MMP3 (0.56) | MEN1KMT2AKDM1ACYP11B1CYP11B2 | |
| SCHEMBL2435624 | 0.79 | MAPT (0.53) | NPC1RAB9AATMMEN1KMT2A | |
| SCHEMBL1765328 | 0.79 | KIF11 (0.59) | NPC1RAB9AKDM1ASMN1; SMN2TDO2 | |
| SCHEMBL851771 | 0.78 | LDHA (0.57) | MEN1KMT2ACYP11B1CYP11B2HSD17B1 | |
| SCHEMBL29392609 | 0.78 | LDHA (0.57) | MEN1KMT2ACYP11B1CYP11B2HSD17B1 | |
| SCHEMBL10717773 | 0.77 | MAPK1 (0.55) | NPC1RXFP1RAB9AATMMEN1 | |
| SCHEMBL28326772 | 0.77 | CYP11B1 (0.44) | NPC1RAB9AATMKDM1AFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387345-A1 | ANTI-CANCER COMPOUNDS ACTING AS NON-PGP SUBSTRATE | ASCENTAWITS PHARMACEUTICALS, LTD. (CN) | 2022-12-08 | — | — | US | disclosed |
| US-20220185793-A1 | COMPOUNDS FOR THE TREATMENT OF ONCOVIRUS INDUCED CANCER AND METHODS OF USE THEREOF | CELLESTIA BIOTECH AG (CH) | 2022-06-16 | — | — | US | disclosed |
| US-20220185793-A1 | COMPOUNDS FOR THE TREATMENT OF ONCOVIRUS INDUCED CANCER AND METHODS OF USE THEREOF | CELLESTIA BIOTECH AG (CH) | 2022-06-16 | — | — | US | disclosed |
| US-20220169642-A1 | COMPOUNDS FOR THE TREATMENT OF ONCOVIRUS INDUCED CANCER AND METHODS OF USE THEREOF | CELLESTIA BIOTECH AG (CH) | 2022-06-02 | — | — | US | disclosed |
| US-20220169642-A1 | COMPOUNDS FOR THE TREATMENT OF ONCOVIRUS INDUCED CANCER AND METHODS OF USE THEREOF | CELLESTIA BIOTECH AG (CH) | 2022-06-02 | — | — | US | disclosed |
| US-20220119429-A1 | FLUORINE-CONTAINING COMPOUND AND ANTI-CANCER MEDICAL USE THEREOF | ASCENTAWITS PHARMACEUTICALS, LTD. (CN) | 2022-04-21 | — | — | US | disclosed |
| EP-3953335-A1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | Cellestia Biotech AG (CH) | 2022-02-16 | — | — | EP | disclosed |
| EP-3952997-A1 | COMPOUNDS FOR THE TREATMENT OF ONCOVIRUS INDUCED CANCER AND METHODS OF USE THEREOF | Cellestia Biotech AG (CH) | 2022-02-16 | — | — | EP | disclosed |
| CN-114007696-A | Compounds for treating oncovirus-induced cancer and methods of use thereof | 塞莱斯蒂亚生物技术股份公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-113966324-A | NOTCH signaling pathway inhibitors and their use in cancer treatment | 塞莱斯蒂亚生物技术股份公司 | 2022-01-21 | — | — | CN | disclosed |
| CN-101208328-A | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals | SANOFI AVENTIS (FR) | 2008-06-25 | — | — | CN | disclosed |
| US-20080108662-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATOR | CHU CHANG A | 2008-05-08 | — | — | US | disclosed |
| US-7355049-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE INC. (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1899321-A1 | HETEROARYL-SUBSTITUTED AMIDES COMPRISING A SATURATED LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-03-19 | — | — | EP | disclosed |
| EP-1663936-B1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | EP | disclosed |
| EP-1741709-A1 | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals | Sanofi-Aventis Deutschland GmbH (DE) | 2007-01-10 | — | — | EP | disclosed |
| WO-2007000246-A1 | HETEROARYL-SUBSTITUTED AMIDES COMPRISING A SATURATED LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-01-04 | — | — | WO | disclosed |
| CN-1812956-A | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN LA ROCHE (CH) | 2006-08-02 | — | — | CN | disclosed |
| EP-0440771-A1 | 5-OXY-2-PHENYLAZINES AND MESOMORPHOUS MEDIUM | MERCK PATENT GmbH (DE) | 1991-08-14 | — | — | EP | disclosed |
| WO-1991002726-A1 | 5-OXY-2-PHENYLAZINES AND MESOMORPHOUS MEDIUM | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1991-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169642-A1 | COMPOUNDS FOR THE TREATMENT OF ONCOVIRUS INDUCED CANCER AND METHODS OF USE THEREOF | NOTCH1, NOTCH4, NOTCH2 | NPC1 1517/4885RXFP1 3663/4885RAB9A 1828/4885 |
| US-20220119429-A1 | FLUORINE-CONTAINING COMPOUND AND ANTI-CANCER MEDICAL USE THEREOF | FLI1, FOLR2, FOLR1 | NPC1 192/4885RXFP1 1478/4885RAB9A 384/4885 |
| US-20080108662-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATOR | GYS2, PYGL, GYS1 | NPC1 1670/4885RXFP1 1569/4885RAB9A 4229/4885 |
| US-20220185793-A1 | COMPOUNDS FOR THE TREATMENT OF ONCOVIRUS INDUCED CANCER AND METHODS OF USE THEREOF | TP53, HAVCR2, AQP1 | NPC1 150/4885RXFP1 4288/4885RAB9A 398/4885 |
| US-20220387345-A1 | ANTI-CANCER COMPOUNDS ACTING AS NON-PGP SUBSTRATE | ABCB1, ABCB11, IMPA1 | NPC1 37/4885RXFP1 2410/4885RAB9A 2493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.